]>
IRCT138706061113N1 IRCT 2010-03-27 Qazvin University of Medical Sciences, Zahravi drug company The effect of omega3 supplementation in preeclampsia in pregnant women at risk in Qazvin The effect of omega3 supplementation in preeclampsia in pregnant women at risk in Qazvin 2007-09-23 anticipated 100 Complete https://irct.ir/trial/145 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention. N/A Preeclampsia. Intervention 1: Omega-3, 1gram for 24 weeks. Intervention 2: Placebo for 24 weeks. Background :Identification of factors preventing from preeclampsia in high risk pregnant women is a significant importance.Omega-3 supplementation may reduce the risk of preeclampsia.<br /> Objective : In this research was assessed the effects of Omega-3 supplementation,on high risk pregnancy for preeclampsia in Qazvin city.<br /> Methods:This single-blind randomized clinical trial was conducted in Qazvin city. The sample was 100 high risk pregnant women for preeclampsia(between 14-18weeks of gestation). 50were assigned to Omega-3 group and 50 to the placebo group.Women were assigned to daily supplementation with 1000mg omega-3 or placebo until delivery.Then preeclampsia and pregnancy outcome's were assessed in two groups.After employing data were recoeded and analyzed statistically using t-test,X2,mannwhitney and fisher exact test.<br /> findings :There were significant differences between the Omega-3 and Placebo groups in the rate(p=0.015) and intensity(P=0.01) of preeclampsia.The correlation was found between the Omega-3 group and outcome of pregnancy (birth weight and Apgar score)( P=0.000,p=0.002).<br /> Conclusion :Our results suggest that supplementation with Omega-3 during pregnancy reduced the risk of preeclampsia in high risk pregnant womenThus it seems necessary to promot educational nutritiant programs for pregnant women .<br /> Keywords : high risk pregnancy,preeclampsia,fatty acids with long chins of omega3
public Fatemeh Ranjkesh
p.o.box: 34197-59811, nursing and midwifery faculty, Qazvin University of Medical Sciences
Qazvin Iran (Islamic Republic of) +98 28 1377 4540 franjkesh@qums.ac.ir nursing and midwifery school scientific Fatemeh Ranjkesh
p.o.box: 34197-59811, nursing and midwifery faculty, Qazvin University of Medical Sciences
Qazvin Iran (Islamic Republic of) +98 28 1377 4540 franjkesh@qums.ac.ir nursing and midwifery school Iran (Islamic Republic of) Inclusion criteria: pregnant women whose gestational age is between 14 to 18 weeks and are ready to cooperate, being high risk for preeclampsia (first gravidy, under the age of 20 and over 40, a history of preeclampsia during the previous gravidy or immediate member of family, BMI more than 29, history of twin fetuses); Inclusion criteria: consumption of Aspirin, Calcium, anticoagulants, allergy to omega3 or fish, presence digestive diseases which need to treatment, 15 years 45 years Female 014 Gestational [pregnancy-induced] hypertension with significant proteinuria Treatment - Drugs Placebo Omega-3, 1gram for 24 weeks Placebo for 24 weeks Hypertention. Timepoint: Every 4 hours. Method of measurement: determination of BP by the auscullatory method. Proteinuria. Timepoint: daily. Method of measurement: Urine Protein. Level of liver enzymes. Timepoint: daily. Method of measurement: laboratory. Headache. Timepoint: Every 4 hours. Method of measurement: Asking from patients. Thrombocytopenia. Timepoint: daily. Method of measurement: laboratory. Abdominal pain. Timepoint: Every 4 hours. Method of measurement: Asking from pateints. Vision problems. Timepoint: Every 4 hours. Method of measurement: Asking from patients. Qazvin University of Medical Sciences, Zahravi drug company Approved 2007-09-21 Qazvin University of Medical Sciences, Deputy for research Deputy for research, Qazvin University of Medical Sciences, Shahid Bahonar blvd. Qazvin Iran (Islamic Republic of)